Comparison of the treatment effects of ossein-hydroxyapatite compound and calcium carbonate in osteoporotic females.
The aim of the study was to evaluate whether ossein-hydroxyapatite (OHC) is more effective than calcium carbonate (CC) in preventing further bone loss in postmenopausal osteoporosis. Forty osteoporotic patients were monitored for 20 months. The patients were randomly assigned to one of two groups and treated in a double-masked manner with 1400 mg calcium per day, in the form of either OHC or CC. OHC consists of hydroxyapatite, collagens and non-collagenous proteins/peptides containing insulin-like growth factor I (IGF-I; 1341 ng), insulin-like growth factor II (IGF-II; 670 ng), transforming growth factor beta (TGF-beta; 166 ng) and osteocalcin (47 micrograms). The bone densities were evaluated at intervals of 4 months with high-precision peripheral quantitative computed tomography. After 20 months of treatment the loss of trabecular bone was 0.8 +/- 0.5% in the OHC group and 1.8 +/- 0.7% in the CC group. The difference between the OHC and CC groups was statistically significant. This study shows that OHC is more effective than CC in slowing peripheral trabecular bone loss in patients with manifest osteoporosis.
Rüegsegger
P
P
Institute for Biomedical Engineering, University and Federal Institute of Technology, Zurich, Switzerland.
Keller
A
A
Dambacher
M A
MA
D000368:Aged; D015519:Bone Density; D002119:Calcium Carbonate / Q000627:therapeutic use*; D004311:Double-Blind Method; D017886:Durapatite / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy*; D011884:Radius / Q000000981:diagnostic imaging; D013977:Tibia / Q000000981:diagnostic imaging; D014057:Tomography, X-Ray Computed
D017886:Durapatite; D002119:Calcium Carbonate